查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2014713

HIV和AIDS診斷市場：按檢測類型、產品類型、檢測方法、最終用戶和應用分類－2026年至2032年全球市場預測

HIV or AIDS Diagnostics Market by Test Type, Type of Product, Testing Method, End-User, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，愛滋病毒和愛滋病診斷市場價值將達到 26 億美元，到 2026 年將成長到 27.6 億美元，到 2032 年將達到 40.6 億美元，年複合成長率為 6.56%。

主要市場統計數據
基準年 2025 26億美元
預計年份：2026年 27.6億美元
預測年份 2032 40.6億美元
複合年成長率 (%) 6.56%

快速的技術進步和策略夥伴關係如何重新定義愛滋病毒和愛滋病的診斷解決方案，以改善早期檢測和病患治療效果。

近年來，在分子生物學和數位健康領域突破性進展以及對病毒病理學更深入理解的推動下，愛滋病毒/愛滋病診斷領域發生了顯著變化。如今的診斷生態系統已遠遠超越了傳統的檢查室環境，涵蓋了快速照護現場（POC​​）平台、居家自測方案以及為臨床醫生提供即時資訊的整合數據分析。早期準確檢測仍然是有效患者管理的基礎，而多抗體檢測和新一代病毒量測量技術的進步正在解決檢測靈敏度和結果返回時間的關鍵挑戰。此外，診斷技術開發商、公共衛生機構和社區組織之間的合作正在擴大服務範圍，並確保弱勢群體能夠公平地獲得檢測服務。

新的即時檢測技術和綜合護理模式正在改變全球愛滋病毒和愛滋病的診斷模式。

在新型即時檢測技術和整合式醫療模式的推動下，愛滋病毒/愛滋病診斷領域的創新正以前所未有的速度發展，這些技術和模式旨在解決長期以來的檢測可及性和速度方面的挑戰。雖然檢查室檢測平台在病毒量定量方面仍然具有無可比擬的靈敏度，但攜帶式免疫檢測分析儀和核酸擴增設備的普及使得臨床醫生即使在偏遠地區也能提供當日檢測結果。同時，自測檢測套組賦予個人自主管理自身健康的能力，減少了社會歧視，並擴大了傳統基礎設施薄弱社區的檢測覆蓋範圍。

到 2025 年，評估美國關稅對 HIV 和 AIDS 診斷產品的供應鏈、定價結構和全球市場動態的累積影響。

美國2025年實施的關稅政策為整個愛滋病診斷供應鏈帶來了新的趨勢，影響了成本結構、籌資策略和區域夥伴關係。對受影響地區生產的試劑和耗材分階段徵收的關稅迫使一些供應商重新評估其採購策略，並考慮在區域內製造地。因此，製造商正在加快建立關鍵檢測組件的本地生產設施，以減少對跨境運輸的依賴，並降低未來關稅變化帶來的風險。

揭示了 HIV 和 AIDS 診斷中按檢測類型、產品、方法、最終用戶和應用分類的關鍵市場細分見解。

要深入了解愛滋病毒（HIV）和愛滋病（AIDS）的診斷，需要全面考慮構成整個市場的多種檢測類型、產品類型、調查方法、終端用戶環境和應用領域。抗體檢測仍是基礎檢測手段，包括酵素免疫分析法試驗（ELISA）、快速層析法平台和確證性西方墨點法，每種方法都滿足不同的操作需求和靈敏度要求。 CD4細胞數和病毒量定量對於疾病分期和治療監測仍然至關重要，這主要得益於流式細胞技術、基於PCR的安瓿瓶和創新的微流體技術。同時，從專用酵素基材到冷凍乾燥PCR預混液，以及將樣本製備、擴增和檢測整合到高效工作流程中的儀器和試劑盒，整體情況塑造了整個診斷格局。

分析影響美洲、歐洲、中東和非洲以及亞太地區愛滋病毒和愛滋病診斷領域成長和創新的關鍵區域趨勢。

區域趨勢對愛滋病毒和愛滋病診斷的發展有顯著影響。在美洲，包括北美成熟的醫療體系和拉丁美洲的新興市場，隨著公共衛生篩檢工作的擴展，先進分子檢測方法的應用正在穩步推進。該地區的相關人員受益於健全的法規結構、大量的研發投入以及政府機構與私人實驗室之間的合作，這些因素正在加速早期檢測宣傳活動和治療監測計畫的發展。相較之下，歐洲、中東和非洲的需求則各不相同：高所得國家正在採用次世代定序進行抗菌素抗藥性分析，而低收入地區則正在利用就地檢驗和自測解決方案來克服基礎設施的限制，並惠及服務不足的社區。

介紹在愛滋病毒和愛滋病診斷領域推動創新、夥伴關係和策略舉措的主要企業。

在策略性收購、突破性創新和廣泛分銷網路的推動下，領先的診斷公司持續引領愛滋病毒和愛滋病檢測領域的發展。全球醫療技術公司透過與專注於快速檢測開發和數位化連接解決方案的生物技術Start-Ups建立有針對性的合作關係，強化了自身的產品組合。這些夥伴關係催生了整合血清學、細胞學和分子檢測以及雲端報告功能的整合平台，從而滿足了檢查室的準確性和即時檢測的便捷性這兩大需求。

為產業領導者應對診斷領域的監管變化、技術進步和競爭壓力提供實用建議。

隨著愛滋病毒和愛滋病診斷日益複雜，產業領導者應優先考慮供應鏈多元化，建立區域製造合作夥伴關係並制定緊急採購方案。採用模組化儀器設計和靈活的試劑規格將有助於快速應對關稅變化和監管政策調整。同時，將人工智慧 (AI) 分析技術整合到診斷流程中，將提升預測能力，支援臨床決策，並最佳化疾病監測活動。基於這些技術基礎，我們鼓勵相關人員與遠端保健提供者和當地機構建立夥伴關係，以擴大服務覆蓋範圍並加強感染後醫療保健的協作。

本文概述了一種穩健的調查方法，該方法利用一手和二手資料對 HIV 和 AIDS 診斷市場進行全面分析。

本研究採用嚴謹的多層次調查方法，首先對主要地理區域的關鍵意見領袖（KOL）、檢查室管理人員、監管專家和採購負責人進行初步訪談，然後對同行評審期刊、技術白皮書、專利申請、監管資料庫和公共衛生出版刊物進行全面審查，以掌握最新的創新成果和政策趨勢。最後，運用資料三角驗證法檢驗趨勢、識別新的應用，並解決專有資訊和開放原始碼資訊之間的差異。

總結主要研究結果和策略意義，以指南不斷發展的愛滋病毒和愛滋病診斷生態系統中的相關人員。

總之，愛滋病毒/愛滋病診斷領域正處於關鍵的轉折點，其特點是技術創新加速發展、監管環境不斷變化以及檢測去中心化程度日益提高。先進的照護現場（POC​​）平台、與數位醫療的融合以及模組化試劑的結合正在重新定義臨床路徑，並為患者提供及時、有效的檢測結果。基礎設施成熟度、政策框架和公私合營所反映的區域差異凸顯了製定在地化策略的必要性，這些策略既要滿足大規模篩檢的需求，又要滿足專業監測的要求。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：按檢測類型分類的愛滋病毒和愛滋病診斷市場

  • 抗體檢測
    • ELISA/EIA
    • 快速檢測
    • 西方墨點法法
  • CD4 偵測
  • 病毒量檢測

第9章：按產品類型分類的愛滋病毒和愛滋病診斷市場

  • 耗材和試劑
  • 設備和工具包
  • 軟體
  • 檢查服務

第10章：依檢測方法分類的愛滋病毒和愛滋病診斷市場

  • 檢查室檢測
  • 即時檢測
  • 自我檢查

第11章 HIV和AIDS診斷市場：按最終用戶分類

  • 血庫和輸血中心
  • 診斷中心
  • 居家醫療環境
  • 醫院和診所
  • 研究機構

第12章 HIV和AIDS診斷市場：按應用分類

  • 疾病進展
  • 監測
  • 篩檢

第13章 愛滋病毒與愛滋病診斷市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 HIV與AIDS診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 愛滋病毒和愛滋病診斷市場：按國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國愛滋病毒與愛滋病診斷市場

第17章：中國的愛滋病診斷市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • ACON Laboratories
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories
  • bioMerieux SA
  • Chembio Diagnostics, Inc.
  • Danaher Corporation
  • DiaSorin SpA
  • ELITechGroup
  • Euroimmun Medizinische Labordiagnostika AG
  • F. Hoffmann-La Roche Ltd.
  • Hologic, Inc.
  • InBios International, Inc.
  • OraSure Technologies
  • Ortho Clinical Diagnostics, Inc.
  • SD Biosensor Inc.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific, Inc.
  • Trinity Biotech plc
  • Viracor Eurofins Diagnostic Services
  • Wondfo Biotech Co. Ltd.
Product Code: MRR-437E9896A55D

The HIV or AIDS Diagnostics Market was valued at USD 2.60 billion in 2025 and is projected to grow to USD 2.76 billion in 2026, with a CAGR of 6.56%, reaching USD 4.06 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.60 billion
Estimated Year [2026] USD 2.76 billion
Forecast Year [2032] USD 4.06 billion
CAGR (%) 6.56%

How Rapid Advances and Strategic Collaboration Are Redefining HIV and AIDS Diagnostic Solutions to Enhance Early Detection and Patient Outcomes

The landscape of HIV and AIDS diagnostics has undergone remarkable transformation in recent years, driven by breakthroughs in molecular biology, digital health, and a deeper understanding of viral pathophysiology. Today's diagnostic ecosystem extends far beyond traditional laboratory settings, incorporating rapid point-of-care platforms, home self-testing solutions, and integrated data analytics that empower clinicians with real-time insights. Early and accurate detection remains the cornerstone of effective patient management, and advances such as multiplex antibody assays and next-generation viral load techniques are closing critical gaps in sensitivity and turnaround time. Furthermore, collaborations between diagnostic developers, public health institutions, and community organizations have amplified reach, ensuring that underserved populations gain equitable access to testing services.

As regulatory agencies accelerate approval pathways for novel diagnostics, there has been an influx of innovative platforms designed to streamline workflows and reduce overall testing costs. Digital connectivity features now embed seamlessly into laboratory information management systems, enabling secure, interoperable data exchange and predictive analytics for patient outcomes. In parallel, the rise of decentralized testing models, supported by portable instruments and smartphone-enabled readers, is bringing HIV diagnostics closer to the point of need. Looking forward, precision diagnostics and adaptive surveillance strategies promise to redefine how clinicians and public health leaders anticipate, monitor, and respond to the evolving HIV and AIDS epidemic.

Emerging Point-Of-Care Technologies and Integrated Care Models Are Driving Transformative Shifts in the Global HIV and AIDS Diagnostic Landscape

Innovation in HIV and AIDS diagnostics is unfolding at an unprecedented pace, catalyzed by emerging point-of-care technologies and integrated care models that address long-standing challenges in access and speed. Laboratory-based platforms continue to offer unparalleled sensitivity for viral load quantification, yet the proliferation of portable immunoassay readers and nucleic acid amplification devices is enabling clinicians to deliver same-visit results in remote settings. Meanwhile, self-testing kits are empowering individuals to engage proactively with their health, reducing stigma and expanding testing coverage in communities where traditional infrastructure may be limited.

In addition, partnerships between diagnostic manufacturers and digital health firms are producing solutions that integrate test results with electronic health records, telemedicine services, and patient support applications. These alliances are accelerating data-driven decision making, driving adherence monitoring, and facilitating linkage to care. Concurrently, regulatory frameworks are evolving to accommodate emergency use authorizations and expedited reviews, especially for diagnostics that demonstrate high clinical utility. Collectively, these trends are reshaping the diagnostic ecosystem, fostering an environment where agility, collaboration, and patient-centric design converge to elevate the standard of HIV and AIDS testing globally.

Assessing the Cumulative Impact of United States Tariffs on HIV and AIDS Diagnostic Supply Chains, Pricing Structures, and Global Market Dynamics by 2025

United States tariffs implemented in 2025 have introduced new dynamics across the HIV and AIDS diagnostic supply chain, affecting cost structures, procurement strategies, and regional partnerships. Reagents and consumables that originate from targeted regions have become subject to incremental duties, leading some suppliers to reevaluate sourcing and to consider regional manufacturing hubs. As a result, manufacturers have accelerated efforts to establish localized production facilities for critical assay components, reducing reliance on cross-border shipments and mitigating exposure to future tariff fluctuations.

These shifts have also prompted diagnostic firms to optimize their product portfolios, prioritizing assays with higher value-added features that can absorb additional costs without compromising clinical affordability. In parallel, research and development investments are focusing on alternative chemistries and modular instrument designs that facilitate in-country assembly and calibration. Even as procurement departments grapple with revised pricing models, procurement teams and policy makers are collaborating to secure volume-based agreements and to streamline customs processes.

Looking ahead, the tariff environment underscores the importance of supply chain resilience. Diagnostic companies are forging strategic alliances with regional suppliers, reinforcing distribution networks, and harnessing digital supply-chain monitoring to anticipate disruptions. Through these adaptive strategies, stakeholders are navigating the tariff landscape while preserving access to essential HIV and AIDS diagnostic services.

Unveiling Critical Market Segmentation Insights Spanning Test Types, Products, Testing Methods, End Users, and Applications in HIV and AIDS Diagnostics

A nuanced understanding of HIV and AIDS diagnostics emerges when considering the variety of test types, products, methodologies, end-user settings, and application areas that collectively define the market. Antibody tests remain fundamental, encompassing enzyme-linked immunosorbent assays, rapid immunochromatographic platforms, and confirmatory Western blot techniques, each catering to distinct operational needs and sensitivity requirements. CD4 cell enumeration and viral load quantification continue to be indispensable for disease staging and treatment monitoring, leveraging flow cytometry, PCR-based amplifiers, and innovative microfluidic approaches. In parallel, the diagnostic landscape is shaped by consumables and reagents, from specialized enzyme substrates to lyophilized PCR master mixes, alongside instruments and kits that integrate sample preparation, amplification, and detection into streamlined workflows.

Software solutions for data management, connectivity, and analytics are emerging as key differentiators, enabling laboratories to aggregate patient data, track epidemiological trends, and support telehealth initiatives. Testing services delivered through centralized laboratories coexist with onsite testing models, such as point-of-care platforms offering rapid turnaround in community clinics, and self-testing kits that empower individuals to conduct HIV screening at home. Blood banks and transfusion centers, diagnostic centers, home care settings, hospitals, clinics, and research institutes each demand tailored diagnostic capabilities, ranging from high-throughput screening to specialized immunophenotyping. Finally, the applications of HIV and AIDS diagnostics span initial screening for seroconversion, monitoring therapeutic efficacy through viral suppression metrics, and assessing disease progression via CD4 count trajectories, driving the continued diversification of assay portfolios.

Analyzing Key Regional Dynamics Shaping Growth and Innovation in HIV and AIDS Diagnostics across the Americas, Europe, Middle East & Africa, and Asia-Pacific

Regional dynamics profoundly influence how HIV and AIDS diagnostics evolve, with the Americas, comprising both mature North American healthcare systems and emerging Latin American markets, demonstrating robust adoption of advanced molecular assays alongside expanded public health screening initiatives. Stakeholders in this region benefit from strong regulatory frameworks, significant R&D investments, and collaborations between government agencies and private sector laboratories, facilitating early detection campaigns and treatment monitoring programs. By contrast, Europe, the Middle East, and Africa present a diverse tapestry of needs, where high-income countries deploy next-generation sequencing for drug resistance analysis and lower-income regions leverage point-of-care and self-testing solutions to overcome infrastructure constraints and reach underserved communities.

Meanwhile, the Asia-Pacific region is witnessing rapid uptake of cost-effective immunoassays, coupled with an increasing emphasis on digital integration and telemedicine platforms. Governments across this region are investing in universal screening programs and public-private partnerships to enhance laboratory capacity and distribute testing kits to rural areas. Multinational diagnostic firms are tailoring portfolios to local regulatory requirements and price sensitivity, while domestic manufacturers are scaling production to meet regional demand. Together, these regional trends underscore the importance of context-specific strategies, where regulatory alignment, supply chain agility, and culturally sensitive outreach determine the success of diagnostic initiatives.

Profiling Leading Industry Players Driving Innovation, Partnerships, and Strategic Initiatives in the HIV and AIDS Diagnostics Sector

A cadre of leading diagnostic companies continues to shape the HIV and AIDS testing landscape, propelled by strategic acquisitions, breakthrough innovations, and expansive distribution networks. Global healthcare technology firms have fortified their portfolios through targeted collaborations with biotechnology startups specializing in rapid test development and digital connectivity solutions. These partnerships are yielding integrated platforms that combine serological, cellular, and molecular assays with cloud-based reporting, meeting the dual demands of laboratory precision and point-of-care convenience.

In response to tariff-induced supply challenges, certain firms have relocated assembly lines closer to key markets, optimizing logistical efficiency and accelerating product delivery. At the same time, a subset of diagnostics innovators is pioneering next-generation technologies-such as CRISPR-based detection systems and microarray workflows-to enable ultra-sensitive, multiplexed screening in resource-limited settings. Meanwhile, several companies are expanding their market reach through alliances with nonprofit organizations and global health initiatives, ensuring their assays are incorporated into large-scale screening and treatment programs. Collectively, these strategic moves and technological investments underscore the competitive rigor and collaborative spirit driving the industry forward.

Delivering Actionable Recommendations for Industry Leaders to Navigate Regulatory Changes, Technological Advancements, and Competitive Pressures in Diagnostics

To navigate the evolving complexities of HIV and AIDS diagnostics, industry leaders should prioritize the diversification of supply chains by forging regional manufacturing alliances and establishing contingency sourcing protocols. Embracing modular instrument designs and flexible reagent formats will enable rapid adaptation to tariff fluctuations and regulatory changes. Simultaneously, integrating artificial intelligence-driven analytics into diagnostic workflows can enhance predictive capabilities, support clinical decision making, and optimize disease surveillance efforts. Building on these technological foundations, stakeholders are encouraged to cultivate partnerships with telehealth providers and community-based organizations to extend reach and improve linkage to care following positive test results.

Investing in workforce development and training programs will ensure that healthcare professionals and laboratory technicians remain proficient in emerging diagnostic methodologies and digital platforms. Moreover, engaging proactively with policymakers can shape favorable regulatory environments for novel diagnostics, including emergency use pathways and accelerated approval mechanisms. Finally, differentiating service offerings through value-added features-such as interoperability, data security, and patient engagement modules-will distinguish organizations in a competitive marketplace and drive sustainable growth.

Outlining a Robust Research Methodology Leveraging Primary and Secondary Sources for Comprehensive Analysis of the HIV and AIDS Diagnostics Market

This research undertook a rigorous, multi-tiered methodology combining primary interviews with key opinion leaders, laboratory directors, regulatory experts, and procurement officers across major geographic regions. Secondary research encompassed a thorough review of peer-reviewed journals, technical whitepapers, patent filings, regulatory databases, and public health agency publications to capture the latest innovations and policy developments. Data were triangulated to validate trends, identify emerging applications, and reconcile discrepancies between proprietary and open-source information.

Quantitative analyses were conducted using anonymized datasets from leading diagnostic manufacturers and service providers, while qualitative insights were gathered through structured discussions with healthcare practitioners and patient advocacy groups. The research framework also integrated comparative case studies of high-impact implementation projects, highlighting best practices in deployment, training, and quality assurance. Finally, findings were subjected to expert peer review to ensure accuracy, relevance, and strategic applicability for stakeholders across the HIV and AIDS diagnostics ecosystem.

Summarizing Core Findings and Strategic Implications to Guide Stakeholders in the Evolving HIV and AIDS Diagnostics Ecosystem

In conclusion, the HIV and AIDS diagnostics sector is at a pivotal juncture, characterized by accelerating technological innovation, shifting regulatory landscapes, and heightened emphasis on decentralizing testing. The interplay of advanced point-of-care platforms, digital health integrations, and modular reagents is redefining clinical pathways and empowering patients with timely, actionable results. Regional nuances-driven by infrastructure maturity, policy frameworks, and public-private collaborations-underscore the need for tailored strategies that address both high-volume screening demands and specialized monitoring requirements.

As tariff regimes introduce new considerations for supply chain resilience and cost management, diagnostic organizations must remain agile, investing in local production capabilities and strategic partnerships. By aligning product development roadmaps with emerging digital tools and evolving care models, stakeholders can enhance diagnostic reach, improve patient outcomes, and sustain competitive differentiation. Ultimately, the synthesis of these trends presents an opportunity for the industry to chart a course toward more accessible, efficient, and patient-centric HIV and AIDS diagnostic solutions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. HIV or AIDS Diagnostics Market, by Test Type

  • 8.1. Antibody Tests
    • 8.1.1. ELISA/EIA
    • 8.1.2. Rapid Tests
    • 8.1.3. Western Blot Test
  • 8.2. CD4 Tests
  • 8.3. Viral Load Tests

9. HIV or AIDS Diagnostics Market, by Type of Product

  • 9.1. Consumables & Reagents
  • 9.2. Instruments & Kits
  • 9.3. Software
  • 9.4. Testing Services

10. HIV or AIDS Diagnostics Market, by Testing Method

  • 10.1. Laboratory-Based Testing
  • 10.2. Point-Of-Care Testing
  • 10.3. Self-Testing

11. HIV or AIDS Diagnostics Market, by End-User

  • 11.1. Blood Banks & Transfusion Centers
  • 11.2. Diagnostic Centers
  • 11.3. Home Care Settings
  • 11.4. Hospitals & Clinics
  • 11.5. Research Institutes

12. HIV or AIDS Diagnostics Market, by Application

  • 12.1. Disease Progression
  • 12.2. Monitoring
  • 12.3. Screening

13. HIV or AIDS Diagnostics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. HIV or AIDS Diagnostics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. HIV or AIDS Diagnostics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States HIV or AIDS Diagnostics Market

17. China HIV or AIDS Diagnostics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. ACON Laboratories
  • 18.7. Beckman Coulter, Inc.
  • 18.8. Becton, Dickinson and Company
  • 18.9. Bio-Rad Laboratories
  • 18.10. bioMerieux SA
  • 18.11. Chembio Diagnostics, Inc.
  • 18.12. Danaher Corporation
  • 18.13. DiaSorin S.p.A.
  • 18.14. ELITechGroup
  • 18.15. Euroimmun Medizinische Labordiagnostika AG
  • 18.16. F. Hoffmann-La Roche Ltd.
  • 18.17. Hologic, Inc.
  • 18.18. InBios International, Inc.
  • 18.19. OraSure Technologies
  • 18.20. Ortho Clinical Diagnostics, Inc.
  • 18.21. SD Biosensor Inc.
  • 18.22. Siemens Healthineers AG
  • 18.23. Thermo Fisher Scientific, Inc.
  • 18.24. Trinity Biotech plc
  • 18.25. Viracor Eurofins Diagnostic Services
  • 18.26. Wondfo Biotech Co. Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA HIV OR AIDS DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ELISA/EIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ELISA/EIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ELISA/EIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY RAPID TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY RAPID TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY RAPID TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY WESTERN BLOT TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY WESTERN BLOT TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY WESTERN BLOT TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY CD4 TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY CD4 TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY CD4 TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY VIRAL LOAD TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY VIRAL LOAD TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY VIRAL LOAD TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS & KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS & KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS & KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY LABORATORY-BASED TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY LABORATORY-BASED TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY LABORATORY-BASED TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY SELF-TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY SELF-TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY SELF-TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY BLOOD BANKS & TRANSFUSION CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY BLOOD BANKS & TRANSFUSION CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY BLOOD BANKS & TRANSFUSION CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY DISEASE PROGRESSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY DISEASE PROGRESSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY DISEASE PROGRESSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. GCC HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GCC HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. GCC HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2032 (USD MILLION)
  • TABLE 139. GCC HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 140. GCC HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 141. GCC HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 142. GCC HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. G7 HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. G7 HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. G7 HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2032 (USD MILLION)
  • TABLE 160. G7 HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 161. G7 HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 162. G7 HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 163. G7 HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. NATO HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. NATO HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. NATO HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2032 (USD MILLION)
  • TABLE 167. NATO HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 168. NATO HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 169. NATO HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 170. NATO HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED STATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED STATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA HIV OR AIDS DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 180. CHINA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. CHINA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY ANTIBODY TESTS, 2018-2032 (USD MILLION)
  • TABLE 182. CHINA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TYPE OF PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 183. CHINA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY TESTING METHOD, 2018-2032 (USD MILLION)
  • TABLE 184. CHINA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 185. CHINA HIV OR AIDS DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)